Halozyme Therapeutics, Inc. (HALO)
NASDAQ: HALO · Real-Time Price · USD
108.17
+2.05 (1.93%)
At close: Aug 21, 2026, 4:00 PM EDT
108.17
0.00 (0.00%)
After-hours: Aug 21, 2026, 6:27 PM EDT
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | 1.04B | 940.33M | 867.84M | 780.29M | 699.31M | 618.59M | 570.99M | 522.62M | |||||||||||||||||||||||
| Royalties Growth | 49.06% | 52.01% | 51.99% | 49.30% | 45.09% | 31.95% | 27.49% | 21.04% | |||||||||||||||||||||||
| Product Sales | 476.94M | 428.83M | 376.44M | 333.14M | 325.57M | 322.95M | 303.49M | 303.73M | |||||||||||||||||||||||
| Product Sales Growth | 46.49% | 32.78% | 24.04% | 9.68% | 7.22% | 8.14% | 0.88% | 7.55% | |||||||||||||||||||||||
| Revenues Under Collaborative Agreements | 144.41M | 139.30M | 152.33M | 129.42M | 153.79M | 142.77M | 140.84M | 121.00M | |||||||||||||||||||||||
| Revenues Under Collaborative Agreements Growth | -6.10% | -2.43% | 8.16% | 6.96% | 75.42% | 49.45% | 74.88% | 81.95% |
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cost of Sales | 292.42M | 259.61M | 228.77M | 192.06M | 186.24M | 179.49M | 159.42M | 169.66M | |||||||||||||||||||||||
| Cost of Sales Growth | 57.01% | 44.64% | 43.51% | 13.20% | 6.39% | -3.25% | -17.13% | -6.87% | |||||||||||||||||||||||
| Selling, General, and Administrative | 238.00M | 222.61M | 207.09M | 172.31M | 167.47M | 161.56M | 154.34M | 149.69M | |||||||||||||||||||||||
| Selling, General, and Administrative Growth | 42.12% | 37.79% | 34.18% | 15.11% | 16.52% | 9.94% | 3.45% | 0.25% | |||||||||||||||||||||||
| Research and Development | 102.37M | 92.25M | 81.49M | 70.03M | 71.24M | 74.74M | 79.05M | 79.94M | |||||||||||||||||||||||
| Research and Development Growth | 43.70% | 23.44% | 3.09% | -12.40% | -9.60% | -3.56% | 3.52% | 3.03% | |||||||||||||||||||||||
| Amortization | 100.16M | 88.41M | 76.66M | 71.05M | 71.05M | 71.05M | 71.05M | 71.05M | |||||||||||||||||||||||
| Amortization Growth | 40.98% | 24.44% | 7.90% | -0.00% | -3.50% | -3.60% | -3.69% | 17.31% |